呼吸道融合细胞病毒药物市场－全球产业规模、份额、趋势、机会、预测：按药物类型、剂型、治疗类型、分销管道、地区和竞争格局划分，2021-2031年

全球呼吸道融合细胞病毒(RSV) 药物市场预计将从 2025 年的 20.4 亿美元成长到 2031 年的 29.3 亿美元，复合年增长率为 6.22%。

该市场涵盖疫苗、预防性单株抗体以及用于治疗或预防下呼吸道感染疾病的治疗药物。推动市场成长的主要因素包括：迫切需要降低婴幼儿和老年人（感染风险较高）的住院率；以及全球人口老化加剧，亟需强有力的预防性医疗保健策略。这些核心驱动因素促进了对有效免疫产品的稳定需求，而该行业具有强大的抗市场波动能力。

另一方面，诸如接种疫苗的犹豫不决以及近期核准产品的推广速度缓慢等因素，是收入成长的主要障碍。对新疫苗的怀疑和公众认知不足常常阻碍这些生物治疗方法的商业性。例如，根据美国国家感染疾病基金会的报告，到2024年，美国60岁及以上成年人的呼吸道融合细胞病毒（RSV）疫苗接种率将仅为24%，凸显了疫苗广泛推广的难度。

市场驱动因素

由于近期监管部门的核准和创新疫苗的推出，全球呼吸道合胞病毒（RSV）药物市场正在经历根本性的变革。针对老年人的标靶疫苗和针对婴幼儿的长效单株抗体的推出，为製药业带来了新的收入来源。这种从症状治疗转向预防医学的趋势，使企业能够在病毒爆发高峰期创造显着价值。赛诺菲在2024年第三季财报中指出，其抗体产品Bayfortus仅在第三季就实现了6.47亿欧元的全球销售额，这充分证明了这一成功。这主要得益于季节性高需求以及该产品迅速被纳入免疫通讯协定，也印证了製药业向预防性生物製药领域转型的合理性。

呼吸道合胞病毒（RSV）相关住院治疗带来的沉重负担是推动相关疫苗上市的关键因素，因为医疗系统正努力控制与严重呼吸系统疾病相关的成本。降低新生儿和老年人等高风险族群住院率的迫切临床需求正在推动这些新疗法的应用。美国疾病管制与预防中心（CDC）在2024年6月的报告中指出，RSV每年导緻美国60岁及以上成年人约10万至16万人住院，凸显了庞大的病患族群亟需治疗。满足此需求的经济规模显而易见，葛兰素史克（GSK）在2023年全年财报中公布，其Alexby疫苗的总销售额达到12亿英镑。

市场挑战

全球呼吸道合胞病毒（RSV）药物市场的商业性扩张主要受疫苗接种意愿低迷和新核准产品推广缓慢的限制。儘管新的预防和治疗方案不断涌现，但普遍存在的怀疑态度和公众认知不足严重限制了可接受治疗的患者群体。这种对生物製药推广的抵制导致研发公司销售量下降，投资回报延迟，因为理论市场规模无法转化为预期的实际收入。因此，企业面临库存积压的困境，并被迫进行高成本、耗时漫长的宣传宣传活动，而这些活动无法即时产生经济效益。

这种市场渗透率低的问题在最需要预防的人群中尤其明显。例如，根据美国疾病管制与预防中心（CDC）的数据，到2024年，2023-2024年度孕妇的呼吸道合胞病毒（RSV）疫苗接种率仅为32.6%。如此低的疫苗接种率清楚地表明，犹豫不决和延迟接种会如何阻碍市场成长。因此，该产业正面临成长停滞，先进治疗方法的经济潜力也因难以获得终端用户的认可而受到限制。

市场趋势

在这一领域，随着mRNA技术平台在新型呼吸道合胞病毒（RSV）疫苗研发中的应用日益广泛，一场革命性的变革正在发生。这使得高效疫苗的快速研发成为可能。这项技术进步超越了传统的蛋白质次单元技术，实现了可扩展的生产规模和针对融合前F蛋白的精准抗原设计。第一款以mRNA为基础的RSV疫苗的核准，充分展现了这项创新，并为未来的生物製药树立了新的标竿。 2024年5月，Moderna公司发布新闻稿宣布，其mRESVIA疫苗已获得美国FDA核准，该疫苗在60岁及以上成年人对RSV引起的下呼吸道疾病的有效率达到83.7%。

此外，小分子口服抗病毒疗法的临床开发平臺进展标誌着治疗策略从传统的预防为主转向急性疾病管理。製药公司正在开发口服疗法，以帮助感染患者，并专注于疫苗接种后的感染病例和未接种疫苗的高风险族群。这些创新治疗方法旨在透过显着抑制病毒复製来减轻症状严重程度并阻止病毒传播。 Enanta Pharmaceuticals公司就是这项进展的典型例证。该公司于2024年9月公布了其IIa期人体挑战试验的主要结果。与安慰剂相比，该公司的口服抗病毒候选药物EDP-323使病毒量曲线下面积降低了85%至87%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：呼吸道融合细胞病毒的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（帕利珠单抗、Ribavirin、其他）
  • 剂型（口服、注射、其他）
  • 治疗类型（抗病毒药物、免疫抑制剂、其他）
  • 分销管道（医院药房、专科药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美呼吸道融合细胞病毒（RSV）药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲呼吸道融合细胞病毒（RSV）药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区呼吸道融合细胞病毒（RSV）药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲呼吸道融合细胞病毒（RSV）药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美呼吸道融合细胞病毒（RSV）药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球呼吸道融合细胞病毒（RSV）药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie, Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck KgaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Respiratory Syncytial Virus (RSV) Drugs Market is projected to expand from USD 2.04 Billion in 2025 to USD 2.93 Billion by 2031, reflecting a compound annual growth rate of 6.22%. This market encompasses vaccines, prophylactic monoclonal antibodies, and therapeutic agents designed to treat or prevent lower respiratory tract infections. Growth is primarily propelled by the urgent necessity to lower hospitalization rates in susceptible infants and seniors, along with the worldwide increase in the aging population that necessitates strong preventive health strategies. These core drivers foster a consistent demand for effective immunizations, distinguishing this sector from transient market fluctuations.

Conversely, the market encounters substantial obstacles related to vaccine hesitancy and the sluggish uptake of recently authorized products, factors that jeopardize revenue growth. Skepticism surrounding new immunizations and insufficient public awareness frequently constrain the commercial reach of these biological treatments. For instance, the National Foundation for Infectious Diseases reported that in 2024, vaccination rates for respiratory syncytial virus among adults aged 60 and older in the United States stood at merely 24%, highlighting the difficulties in achieving widespread adoption.

Market Driver

The Global RSV Drugs Market is being fundamentally transformed by recent regulatory clearances and the rollout of innovative vaccines. The introduction of targeted immunizations for seniors and long-acting monoclonal antibodies for infants has created a new financial foundation for the pharmaceutical industry. This transition from treating symptoms to preventative care enables companies to generate substantial value during peak viral seasons. As evidence of this success, Sanofi reported in its Q3 2024 results that global sales for the antibody Beyfortus hit €647 million in the third quarter alone, driven by robust seasonal demand and quick integration into immunization protocols, validating the industry's pivot toward preventative biologics.

The significant burden of RSV-related hospital admissions serves as a crucial catalyst for market adoption, as healthcare systems strive to control costs linked to severe respiratory illness. The pressing clinical requirement to decrease admission rates among high-risk groups, such as neonates and the elderly, drives the utilization of these new therapeutics. The Centers for Disease Control and Prevention noted in a June 2024 report that RSV causes roughly 100,000 to 160,000 annual hospitalizations among US adults over 60, highlighting the vast patient population needing care. The economic magnitude of meeting this need is clear, with GSK reporting £1.2 billion in total sales for its Arexvy vaccine in its full-year 2023 results.

Market Challenge

Commercial expansion of the Global RSV Drugs Market is significantly hindered by vaccine hesitancy and the slow uptake of newly approved products. Although novel prophylactic and therapeutic options have been introduced, widespread skepticism and a lack of public knowledge severely limit the accessible patient population. This resistance to adopting biological agents results in lower sales volumes and a delayed return on investment for developers, as the theoretical market size does not translate into actual revenue as anticipated. Consequently, companies face the issue of unmoving inventory and the need for expensive, prolonged educational campaigns that fail to deliver immediate financial benefits.

This pattern of weak market penetration is particularly noticeable in demographic segments where protection is most needed. For example, data from the Centers for Disease Control and Prevention indicated that maternal RSV vaccination coverage for the 2023-2024 season was only 32.6% in 2024. Such depressed immunization rates among priority groups clearly illustrate how hesitancy and sluggish adoption curb market growth. As a result, the industry confronts a flattened growth curve where the economic promise of advanced therapies is stifled by the enduring difficulty of securing end-user acceptance.

Market Trends

The sector is being revolutionized by the adoption of mRNA technology platforms for formulating novel RSV vaccines, facilitating the swift creation of highly effective immunizations. This technological advancement surpasses conventional protein subunit techniques by allowing for scalable manufacturing and precise antigen design targeting the prefusion F protein. The approval of the first mRNA-based RSV vaccine served as a validation of this innovation, setting a new standard for future biologics. In a May 2024 press release, Moderna announced that its mRESVIA vaccine received US FDA approval after demonstrating an efficacy of 83.7% against lower respiratory tract disease caused by RSV in adults aged 60 and older.

Furthermore, the advancement of small molecule oral antiviral therapeutics in clinical pipelines marks a significant shift from strictly prophylactic approaches to acute disease management. Pharmaceutical companies are developing oral treatments to help infected patients, specifically addressing cases of vaccine breakthrough or high-risk individuals who remain unvaccinated. These innovative therapies are designed to drastically lower viral replication, thereby reducing symptom severity and halting transmission. Highlighting this progress, Enanta Pharmaceuticals reported positive topline results in September 2024 from a Phase 2a human challenge study, where their oral antiviral candidate EDP-323 achieved an 85% to 87% reduction in viral load area under the curve compared to a placebo.

Key Market Players

• AbbVie, Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Merck KgaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.

Report Scope

In this report, the Global Respiratory Syncytial Virus (RSV) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Syncytial Virus (RSV) Drugs Market, By Drug Type

• Palivizumab
• Ribavirin
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Dosage Form

• Oral
• Injectable
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Treatment Type

• Antiviral Medications
• Immune prophylaxis
• Others

Respiratory Syncytial Virus (RSV) Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Respiratory Syncytial Virus (RSV) Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Syncytial Virus (RSV) Drugs Market.

Available Customizations:

Global Respiratory Syncytial Virus (RSV) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Palivizumab, Ribavirin, Others)
  • 5.2.2. By Dosage Form (Oral, Injectable, Others)
  • 5.2.3. By Treatment Type (Antiviral Medications, Immune prophylaxis, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Dosage Form
  • 6.2.3. By Treatment Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Dosage Form
      • 6.3.1.2.3. By Treatment Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Dosage Form
      • 6.3.2.2.3. By Treatment Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Dosage Form
      • 6.3.3.2.3. By Treatment Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Dosage Form
  • 7.2.3. By Treatment Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Dosage Form
      • 7.3.1.2.3. By Treatment Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Dosage Form
      • 7.3.2.2.3. By Treatment Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Dosage Form
      • 7.3.3.2.3. By Treatment Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Dosage Form
      • 7.3.4.2.3. By Treatment Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Dosage Form
      • 7.3.5.2.3. By Treatment Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Dosage Form
  • 8.2.3. By Treatment Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Dosage Form
      • 8.3.1.2.3. By Treatment Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Dosage Form
      • 8.3.2.2.3. By Treatment Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Dosage Form
      • 8.3.3.2.3. By Treatment Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Dosage Form
      • 8.3.4.2.3. By Treatment Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Dosage Form
      • 8.3.5.2.3. By Treatment Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Treatment Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Treatment Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Treatment Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Treatment Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Respiratory Syncytial Virus (RSV) Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Treatment Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Treatment Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Treatment Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Respiratory Syncytial Virus (RSV) Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Treatment Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Respiratory Syncytial Virus (RSV) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Bausch Health Companies Inc.
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Gilead Sciences, Inc.
• 15.6. GlaxoSmithKline PLC
• 15.7. Merck KgaA
• 15.8. Pfizer Inc.
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Johnson & Johnson Services, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer